Open AccessClinical analysis of G efitinib in the treatment of stage IV lung adenocarcinoma with unknown EGFR gene mutations
Author(s) -
Li Rong,
Lou Yuqing,
Zhang Yanwei,
Shi Chunlei,
Xiong Liwen,
Gu Aiqin,
Han Baohui
Publication year - 2013
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12044
Subject(s) - rash , medicine , diarrhea , adenocarcinoma , stage (stratigraphy) , lung cancer , epidermal growth factor receptor , gastroenterology , tyrosine kinase inhibitor , oncology , lung , adverse effect , gefitinib , receptor , cancer , paleontology , biology
Background As it is difficult to obtain enough histopathological data for epidermal growth factor receptor ( EGFR) gene detection, it is necessary for us to explore how to perform EGFR ‐tyrosine kinase inhibitor ( TKI ) therapy in patients with unknown EGFR gene mutations. Methods We analyzed the efficacy of G efitinib treatment and the clinical characteristics of 214 patients with stage IV lung adenocarcinoma. Results Objective response rates ( ORR) and overall survival (OS) of women were higher than men; ORR of patients with rash, diarrhea, or rash associated with diarrhea, was higher than patients without those side effects. Progression‐free survival ( PFS) of patients with performance status ( PS) scores of 1, 2, and 3 points was 8.0 ± 1.699, 7.3 ± 0.419, and 6.0 ± 2.010, respectively; OS was 26.0 ± 1.536, 16.3 ± 1.262, and 14.3 ± 2.389, respectively. PFS and OS of patients with rash and diarrhea were better than for those without these side effects. In males, the PFS of patients >65 years old versus ≤65 years old was 13.0 ± 2.7 months versus 5.5 ± 0.197 months, respectively. Multivariate analysis showed that PS score, diarrhea, and rash affected the patients' PFS , while gender, PS score, and rash affected the patients' OS . Conclusions In patients with stage IV lung adenocarcinoma and unknown EGFR gene mutations treated with G efitinib, our findings suggest a better prognosis for female patients and those with low PS scores.